Defining the Optimal Treatment Strategy in Patients With Uterine Serous Carcinoma
Authors:
- 9 December 2022
- journal article
- research article
- Published by Elsevier in Clinical Oncology
- Vol. 35 (2) , e199-e205
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- BGCS uterine cancer guidelines: Recommendations for practiceEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2017
- Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trialThe Lancet Oncology, 2016
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial CancerInternational Journal of Gynecological Cancer, 2016
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous CarcinomaInternational Journal of Gynecological Cancer, 2014
- The importance of chemotherapy and radiation in uterine papillary serous carcinomaGynecologic Oncology, 2011
- Long-term survival of endometrioid endometrial cancer patientsArchives of Medical Science, 2010
- Revised FIGO staging for carcinoma of the vulva, cervix, and endometriumInternational Journal of Gynecology & Obstetrics, 2009
- Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: A 12-year experience at Memorial Sloan-Kettering Cancer CenterGynecologic Oncology, 2006
- Uterine papillary serous carcinomaAmerican Journal of Surgical Pathology, 1982